Process & Results

Simple to order. Comprehensive Results.

DecisionDx-Melanoma is for patients diagnosed with invasive cutaneous melanoma – testing is simple to order and can be performed on the diagnostic biopsy or excision procedure. Our DecisionDx-Melanoma testing provides three personalized and actionable results in one comprehensive report.

Ordering DecisionDx-Melanoma

Ordering DecisionDx-Melanoma

The test can be ordered via Castle's online portal or by completing a test request form. Click below to download a request form or register for Castle's clinician portal.

Order a Test

Testing process

The DecisionDx-Melanoma test uses the same tissue from the diagnostic biopsy or excision procedure. This spares your patients additional procedures. Castle coordinates the tissue collection, including shipping, directly with your pathology lab.

Report results

Castle performs the test in a CAP-accredited laboratory and typically delivers the report within 3-5 days from tissue receipt. DecisionDx-Melanoma provides three personalized risk assessments in one comprehensive report.

Download a Sample Report

Patient access

Castle Biosciences is committed to providing high-quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information. We intend to work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance for their Castle test, we offer a comprehensive patient assistance program to all patients.

If you have any questions, please contact us by calling 866-788-9007, option 3 or send an email.

Easy-to-interpret results that help guide risk-aligned care

The comprehensive DecisionDx-Melanoma report provides three personalized risk assessments

31-GEP Class Score

Independently validated, the 31-GEP continuous score is used to provide patient risk by molecular class. 

  • Class 1A: Lowest risk of recurrence and/or metastasis within 5 years 
  • Class 1B/2A: Increased risk of recurrence and/or metastasis within 5 years
  • Class 2B: Highest risk of recurrence and/or metastasis within 5 years 

Individual Risk of Recurrence

By integrating the 31-GEP class score with clinicopathologic factors:

  • Ulceration
  • Age
  • Breslow Thickness
  • Mitotic Rate
  • SLN Status
  • Tumor Location

DecisionDx-Melanoma provides personalized 5-year risk of recurrence estimates for American Joint Committee on Cancer (AJCC) Stage I-II patients for three distinct endpoints: Melanoma specific survival (MSS), distant metastasis free survival (DMFS) and recurrence free survival (RFS). 

Individual Risk of SLN Positivity

By integrating the 31-GEP class score with clinicopathologic factors:

  • Ulceration
  • Breslow thickness
  • Age

DecisionDx-Melanoma provides precise and personalized risk predictions for likelihood of SLNB positivity.

Order a test

Get Started
Next Up

Resources

View More